Live Breaking News & Updates on Clinical Breast Cancer Research|Page 2

Stay updated with breaking news from Clinical breast cancer research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

ADCs, CDK4/6 Inhibitors, and SERDs Broaden HR+ and Triple-Negative Breast Cancer Treatment Paradigms

Novel data with trastuzumab deruxtecan, sacituzumab govitecan, and ribociclib have demonstrated an influx of overall survival advantages compared with standard-of-care regimens across breast cancer patient subsets, including HER2-positive, hormone receptor–positive, and triple-negative disease. ....

United States , Heather Mcarthur , Joyce Oshaughnessy , Breast Cancer Program , Ut Southwestern Medical Center , Department Of Internal Medicine , Clinical Breast Cancer Research , Baylor Charlesa Sammons Cancer Center , Division Of Hematology , Komen Distinguished Chair , Internal Medicine , Medical Center , Shanu Modi , Joyceo Shaughnessy , Texas Oncology Baylor Charles , Cancer Center , Trastuzumab Deruxtecan , Sacituzumab Govitecan , Overall Survival , Her2 Positive Breast Cancer , Hormone Receptor Positive Breast Cancer , Triple Negative Breast Cancer ,

Treatment of HER2-Low Breast Cancer Impacts Oncology Landscape

Because of its prevalence in approximately 50% of breast cancers, the outcomes of HER2-low treatment have a significant impact on patient outcomes. ....

United States , Neelam Patel , Heather Mcarthur , Ut Southwestern Medical Center , Clinical Breast Cancer Research , Department Of Internal Medicine , Breast Cancer Program At Simmons Center , Md Anderson Cancer Center , Oncology Pharmacy Professionals , Komen Distinguished Chair , Internal Medicine , Medical Center , Breast Cancer Program , Simmons Cancer Center , Cancer Center ,